中
Back >>

• Current position：

ASCO 2024 | BlissBio to Present Phase I Clinical Data of Anti-tumor Drug BB-1701 at the 2024 ASCO Annual Meeting

Source: | Author:BlissBio | Published time: 2024-06-01 | 2211 Views | Share:

ASCO 2024  |  BlissBioto Present Phase I Clinical Data of Anti-tumor Drug BB-1701 at the 2024 ASCO Annual Meeting 



HANGZHOU, China, June 1, 2024 – BlissBio announces today the Phase I clinical data of Anti-tumor antibody-drug conjugate (ADC) BB-1701 will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S..

Abstract Title: Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer.

Abstract: 1110

Poster Board: 88

Session Title: Breast Cancer—Metastatic

Session Date and Time: 9:00 AM - 12:00 PM, Sunday, June 2, 2024


In 2023, BlissBio and Eisai Co., Ltd (Headquarter: Tokyo, “Eisai”) entered into a clinical trial collaboration for BB-1701, and BlissBio commits to working with Eisai to advance the development of BB-1701 for the benefit of patients worldwide.





About BB-1701



BB-1701 is an innovative ADC developed by BlissBio consisting of anti-HER2 antibody and eribulin. It is designed to provide a safer and more effective treatment regimen for patients with locally advanced/metastatic HER2 expressing solid tumors and expected to have multiple market prospects for application in various tumor indications. BB-1701 has unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity. BB-1701 is being used to conduct Phase II international clinical trials globally.



Media Inquiries



Bliss Biopharmaceutical (Hangzhou) Co., Ltd

TEL: +86-0571-86808367

E-mail: office@blissbiopharma.com